Chirality in metal-based anticancer agents,Dalton Transactions

当前位置： X-MOL 学术 › Dalton Trans. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Chirality in metal-based anticancer agents
Dalton Transactions ( IF 3.5 ) Pub Date : 2018-02-08 00:00:00 , DOI: 10.1039/c8dt00089a
Yi Wang _{1,

2,

3,

4,

5} , Huaiyi Huang _{6,

7,

8,

9} , Qianling Zhang _{1,

2,

3,

4,

5} , Pingyu Zhang _{1,

2,

3,

4,

5}

Affiliation

Chiral natural biological molecules, such as nucleic acids and proteins, guide the research of chiral compounds. Chiral metal-based drugs are currently an interesting and rapidly growing field in anticancer research. This perspective focuses on chiral metal compounds with application in cancer chemotherapy. The different chiral metal-based anticancer agents and the extent to which the chiral resolution affects their biological properties are discussed. This perspective will aid the design of new potent and efficient chiral metal-based anticancer drugs that exploit their unique properties combined with their potential selectivity toward targeted chiral biomolecules.

中文翻译：

金属基抗癌剂中的手性

手性天然生物分子，例如核酸和蛋白质，指导着手性化合物的研究。基于手性金属的药物目前是抗癌研究中一个有趣且迅速发展的领域。该观点着眼于手性金属化合物及其在癌症化学疗法中的应用。讨论了不同的手性金属基抗癌剂以及手性拆分影响其生物学特性的程度。这种观点将有助于设计新的有效且高效的基于手性金属的抗癌药物，这些药物利用其独特的性能以及对靶向手性生物分子的潜在选择性。

更新日期：2018-02-08

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11